US Patent

US9504655 — Capsule dosage form of metoprolol succinate

Formulation · Assigned to Sun Pharmaceutical Industries Ltd · Expires 2035-07-09 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units.

USPTO Abstract

The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation.

Drugs covered by this patent

Patent Metadata

Patent number
US9504655
Jurisdiction
US
Classification
Formulation
Expires
2035-07-09
Drug substance claim
No
Drug product claim
Yes
Assignee
Sun Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.